HRP20160124T1 - Uporaba spojeva 1h-indazol-3-karboksamida kao inhibitora glikogen sinteze kinaze-3 beta - Google Patents

Uporaba spojeva 1h-indazol-3-karboksamida kao inhibitora glikogen sinteze kinaze-3 beta Download PDF

Info

Publication number
HRP20160124T1
HRP20160124T1 HRP20160124TT HRP20160124T HRP20160124T1 HR P20160124 T1 HRP20160124 T1 HR P20160124T1 HR P20160124T T HRP20160124T T HR P20160124TT HR P20160124 T HRP20160124 T HR P20160124T HR P20160124 T1 HRP20160124 T1 HR P20160124T1
Authority
HR
Croatia
Prior art keywords
disorders
group
carboxamide
indazole
use according
Prior art date
Application number
HRP20160124TT
Other languages
English (en)
Croatian (hr)
Inventor
Maria Alessandra Alisi
Nicola Cazzolla
Barbara Garofalo
Guido Furlotti
Gabriele Magaro'
Rosella Ombrato
Francesca Mancini
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. - S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. - S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. - S.P.A.
Publication of HRP20160124T1 publication Critical patent/HRP20160124T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20160124TT 2012-02-21 2013-02-08 Uporaba spojeva 1h-indazol-3-karboksamida kao inhibitora glikogen sinteze kinaze-3 beta HRP20160124T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12156298 2012-02-21
PCT/EP2013/052523 WO2013124169A1 (en) 2012-02-21 2013-02-08 Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
EP13703799.0A EP2817301B1 (en) 2012-02-21 2013-02-08 Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Publications (1)

Publication Number Publication Date
HRP20160124T1 true HRP20160124T1 (hr) 2016-03-11

Family

ID=47710141

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160124TT HRP20160124T1 (hr) 2012-02-21 2013-02-08 Uporaba spojeva 1h-indazol-3-karboksamida kao inhibitora glikogen sinteze kinaze-3 beta

Country Status (26)

Country Link
US (2) US9163013B2 (https=)
EP (1) EP2817301B1 (https=)
JP (1) JP6285873B2 (https=)
KR (1) KR102101702B1 (https=)
CN (1) CN104080781B (https=)
AR (1) AR090085A1 (https=)
AU (1) AU2013224313B2 (https=)
BR (1) BR112014018657B1 (https=)
CA (1) CA2860466C (https=)
CY (1) CY1117467T1 (https=)
DK (1) DK2817301T3 (https=)
EA (1) EA026952B1 (https=)
ES (1) ES2564033T3 (https=)
GE (1) GEP201606552B (https=)
HR (1) HRP20160124T1 (https=)
HU (1) HUE027445T2 (https=)
IL (1) IL233825A (https=)
MX (1) MX351288B (https=)
PL (1) PL2817301T3 (https=)
PT (1) PT2817301E (https=)
RS (1) RS54539B1 (https=)
SG (2) SG11201403788VA (https=)
SI (1) SI2817301T1 (https=)
SM (1) SMT201600054B (https=)
UA (1) UA113189C2 (https=)
WO (1) WO2013124169A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014018657B1 (pt) * 2012-02-21 2022-08-02 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A Compostos de 1h-indazol-3-carboxamida
EP3190889B1 (en) 2014-09-03 2021-11-17 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN107709314A (zh) 2015-06-11 2018-02-16 巴斯利尔药物国际股份公司 外排泵抑制剂及其治疗性用途
WO2017093157A1 (en) * 2015-11-30 2017-06-08 Basilea Pharmaceutica Ag Piperidine, pyrrolidine and 2-oxo-1,3-oxazinane derivatives as inhibitors of bacterial efflux-pumps for the treatment of microbial infections
CA3026982A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
ES2913975T3 (es) 2018-05-07 2022-06-07 Acraf Compuestos de 1H-indazol-3-carboxamida como inhibidores de la glucógeno sintasa cinasa-3 beta
EP3849968B1 (en) 2018-09-13 2022-12-21 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
EP3849969B1 (en) 2018-09-13 2023-04-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
CN117186027B (zh) * 2023-09-11 2024-04-19 上海蓝木化工有限公司 一种糖原合酶激酶-3抑制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0667867A1 (en) 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
DE69627323T2 (de) 1995-05-31 2004-01-15 Nisshin Seifun Group Inc Indazolderivate mit einer cyclischen aminogruppe
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
ITMI20030287A1 (it) 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
ITMI20030972A1 (it) 2003-05-15 2004-11-16 Acraf Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
UA99927C2 (uk) 2007-11-12 2012-10-25 Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. Медикамент, який є активним при невропатичному болі
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US7947728B1 (en) * 2009-11-11 2011-05-24 Hoffmann-La Roche Inc. Indole and indazole analogs as glycogen synthase activators
BR112014018657B1 (pt) * 2012-02-21 2022-08-02 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A Compostos de 1h-indazol-3-carboxamida
AU2013224302B2 (en) * 2012-02-21 2017-03-30 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Also Published As

Publication number Publication date
MX2014009298A (es) 2014-10-14
US20160045485A1 (en) 2016-02-18
PT2817301E (pt) 2016-03-14
EA201491448A1 (ru) 2014-11-28
SI2817301T1 (sl) 2016-03-31
IL233825A0 (en) 2014-09-30
BR112014018657B1 (pt) 2022-08-02
US9163013B2 (en) 2015-10-20
CN104080781B (zh) 2016-05-11
AU2013224313A8 (en) 2014-09-18
KR20140122725A (ko) 2014-10-20
HK1203931A1 (zh) 2015-11-06
EA026952B1 (ru) 2017-06-30
UA113189C2 (xx) 2016-12-26
CY1117467T1 (el) 2017-04-26
ES2564033T3 (es) 2016-03-17
SG10201701171TA (en) 2017-04-27
CA2860466C (en) 2020-02-18
BR112014018657A2 (https=) 2017-06-20
BR112014018657A8 (pt) 2017-07-11
MX351288B (es) 2017-10-09
PL2817301T3 (pl) 2016-05-31
HUE027445T2 (en) 2016-09-28
DK2817301T3 (en) 2016-03-14
AR090085A1 (es) 2014-10-15
GEP201606552B (en) 2016-10-10
EP2817301A1 (en) 2014-12-31
CA2860466A1 (en) 2013-08-29
WO2013124169A1 (en) 2013-08-29
KR102101702B1 (ko) 2020-04-20
AU2013224313B2 (en) 2017-03-30
SG11201403788VA (en) 2014-08-28
SMT201600054B (it) 2016-04-29
RS54539B1 (sr) 2016-06-30
US20140378455A1 (en) 2014-12-25
AU2013224313A1 (en) 2014-07-17
CN104080781A (zh) 2014-10-01
JP2015506995A (ja) 2015-03-05
JP6285873B2 (ja) 2018-02-28
US9700551B2 (en) 2017-07-11
EP2817301B1 (en) 2015-12-23
IL233825A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
HRP20160124T1 (hr) Uporaba spojeva 1h-indazol-3-karboksamida kao inhibitora glikogen sinteze kinaze-3 beta
HRP20160125T1 (hr) Spojevi 1h-indazol-3-karboksamida kao inhibitori glikogen sinteze kinaze-3 beta
JP2015506993A5 (https=)
AR091236A1 (es) Compuestos de tetrahidropirazolopirimidina
PE20160126A1 (es) Derivados del bipirazol como inhibidores jak
MX2012015105A (es) Inhibidores de cinasa de regulacion mediante señal de apoptosis.
MX374409B (es) Derivados de etinilo como moduladores del receptor de glutamato metabotrópico.
CY1117580T1 (el) Νεα ετεροκυκλικα παραγωγα και η χρηση τους στη θεραπεια νευρολογικων διαταραχων
MX353957B (es) Carboxamidas heterociclicas fungicidas.
NZ601967A (en) Pde10 inhibitors and related compositions and methods
MX2015009986A (es) Agonistas del receptor de esfingosina-1-fosfato, metodos para prepararlos y composiciones farmaceuticas que contienen los mismos como un agente activo.
MX2011008501A (es) Compuestos heterociclicos fusionados que contienen nitrogeno y su uso como inhibidores de la produccion de beta-amiloide.
AR078920A1 (es) Compuestos de pirrolopiridina como moduladores de quinasas. procesos de obtencion y composiciones farmaceuticas.
JP2013507336A5 (https=)
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
NZ739429A (en) Liquid pharmaceutical compositions comprising sglt-2 inhibitors
EA201070864A1 (ru) Новые гетероциклические соединения
HK1220325A1 (zh) 苯并咪唑衍生物及其用途
MX2010009462A (es) Derivados de indazol.
RU2008135332A (ru) Ингибиторы киназ и способы их применения
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
RU2020123899A (ru) Новые соединения, ингибирующие mtor
AR062013A1 (es) Derivados cromenos o tiocromenos carboxamidas, su procedimiento de preparacion y sus aplicaciones en terapeutica
PH12022551507A1 (en) Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
MX2016002717A (es) Derivado de etinilo.